Search

Geoffrey M. Hodgson Is There A Future For Heterodox Economics? Institutions, Ideology and A Scientific Community Edward Elgar, Cheltenham, 2019, 353pp., $52, paperback. The tone of this book is unremittingly [...]

Geoff Mann In the long run we are all dead: Keynesianism, political economy and revolution Verso, London, 2017, 416pp., $40, hardback. 'Keynes was in no way the first Keynesian', Geoff [...]

John E King Advanced Introduction to Post Keynesian Economics. Edward Elgar, 2015, pp.140. c. A$40. Post-Keynesian political economy has in recent times established itself as the most exciting and rewarding [...]

In this article we review the Accord between the Australian Labor Party (ALP) and the Australian Council of Trade Unions (ACTU), in order to address current uncertainty over the role of unions in politics, particularly in the face of both the Coalition Government's 2006 industrial relations legislation and the ALP's apparent repudiation of the country's longstanding institutional leverage over wages and non-wage policies. The Accord exemplified an explicitly corporatist union strategy and it initially attracted extensive and hostile commentary. However, discussion of the experiment, together with other tripartite approaches to policy formation, has waned in recent years, perhaps suggesting that it was a tactic whose time has passed. Reviewing some major criticisms, we argue that critics have dismissed the Accord too hastily. Although serious problems with the Accord process are acknowledged, the articulation of a broad program of social democratic initiatives is always likely to retain support on the political left. Despite changes in union density and workforce composition, the union movement still possesses capacity to mobilise community support and develop a principled program.

This paper surveys hostile reactions to claims that the 11 September attacks were understandable in terms of the actions of the west towards poor parts of the world and the rich countries' own public commitments to democracy and affluence at home. The paper argues that domestic resentment is likely to continue to foment because concerted institution-building commensurate with the rich countries' material capacities has been neglected. Much responsibility for the global discontent can be attributed to policies advocated by the west and imposed on both rich and poor countries alike by policy-elites within the countries. Intellectuals have a role in re-activating the sorts of high-minded state-building and policymaking capacities that preoccupied them in the immediate post-1945 period.

Joan Robinson (1903-1983) contributed for the post-Keynesian critique of liberalism. She characterized orthodox economic theory as a formalist desert.

Background Tafenoquine was recently approved for chemoprophylaxis of malaria. Its specific activity against liver and blood stages of Plasmodium species has been separately characterized in animals but not in humans. Methods In this randomized, double-blind, placebo-controlled study, 16 malaria-naive, glucose-6-phosphate dehydrogenase–normal participants aged 20–42 years received tafenoquine chemoprophylaxis prior to challenge with blood stage Plasmodium falciparum. Participants were randomly assigned to either tafenoquine (n = 12) or placebo (n = 4) and took blinded study medication (single 200-mg dose) on days 1, 2, 3, and 10, followed by intravenous inoculation with approximately 2800 P. falciparum parasitized erythrocytes on day 13. The primary endpoint was the number of participants requiring rescue treatment with artemether/lumefantrine due to the onset of parasitemia as determined by quantitative polymerase chain reaction. Results None of the 12 participants who received tafenoquine developed parasitemia, whereas all placebo participants developed parasitemia (P =.0005). Two cases of mild hemoglobin decrease and a single case of mild hyperbilirubinemia occurred in the tafenoquine group. Conclusions Tafenoquine chemoprophylaxis is safe and effective in preventing malaria in healthy nonimmune participants challenged with blood stage P. falciparum. Clinical Trials Registration Australian and New Zealand Clinical Trials Registry (ANZCTR): ACTRN12617000102370. [ABSTRACT FROM AUTHOR]